Abbott clot-busting drug may extend window of time for treating patients
Article Abstract:
Abbott Labs is pleased with the results of a study on 180 stroke patients using its new drug called prourokinase. The drug, if and when approved by the FDA, would be an alternative to heparin as an anti-clot medication. A major improvement is that the medication helps victims of stroke if administered within six hours rather than the current option, a drug from Genentech that needs to be given within three hours of the onset of the stroke. Part of the challenge with prourokinase is that it is not given intravenously, but through a catheter into the brain, meaning training and expertise would typically be found only at large teaching hospitals. Also, one side effect is greater incidence of brain hemorrhage than with heparin or Genentech's Activase.
Comment:
New stroke treatment looks promising, but NDA has not been filed yet
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Oxford outlines plan to improve its performance
Article Abstract:
Oxford Health Plans Inc. outlines plans to improve its performance. The plan is aimed at returning the health maintenance organization to break even financial performance within 12 months. It will bring higher rates for employers, less flexibility for patients and lower fees for physicians and other providers. "Oxford is walking a very fine line between balancing its needs to restore profitability and going against the branded name it has established," said Bob Braddick, a consultant with William M. Mercer Inc.
Comment:
Oxford outlines plans to improve its performance
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Strategic costing and financial reporting. Strategic costing and special studies
- Abstracts: GM is closing rest of North American operations. GM to make Delphi Unit independent GM shutdown looms in North America
- Abstracts: Cisco planning an alternative to traditional switch systems
- Abstracts: Imaginative supplements help a pair of magazines build relationships with marketers. A new spot for Chanel No. 5 dabs on some sex and surrealism
- Abstracts: Vencor is bruised by government health-care changes. Vencor expects per-share loss of 10 to 15 cents. Vencor co-founder Lunsford resigns, saying company has outgrown him